Research Group Leader
European Bioinformatics Institute EMBL-EBI
Moritz Gerstung leads a research group at EMBL-EBI investigating the underlying mechanisms of cancer development and seeking to understand the differences in therapy success and outcomes in different individuals. His team develops statistical models for relating different layers of genomic, molecular and clinical data to establish connections between genotype and phenotype, and tools to predict outcomes based on comprehensive, high-dimensional datasets. He has a PhD in Computational Biology from ETH Zurich (2012), and carried out postdoctoral work at the Wellcome Trust Sanger Institute (2012-2015).
Precision oncology for myeloid leukemia using knowledge banks
Underpinning the vision of precision medicine is the concept that mutations in a patient’s cancer drive its biology and treatment response. Here, by reanalyzing data from 1,540 patients with acute myeloid leukemia (AML), we explore how large knowledge banks of matched genomic-clinical data can support clinical decision-making. Personally tailored management decisions based on statistical models trained on the knowledge bank could reduce the number of hematopoietic cell transplants in patients with AML by 20-25% while maintaining overall survival rates. Knowledge banks facilitate personally tailored therapeutic decisions but require sustainable updating, inclusive cohorts and large sample sizes.
- IMPACT Session II: Impact on Medical Professions and Healthcare Providers on November 20, 2017 3:45 pm